MARY HITCHCOCK MEMORIAL HOSP
1. Target Overview & Investment Thesis
MARY HITCHCOCK MEMORIAL HOSP is a 456-bed large academic medical center in GRAFTON, NH with $1.43B in net patient revenue and a -33.9% operating margin. The hospital serves a payer mix of 33.7% Medicare, 0.9% Medicaid, and 65.4% commercial.
Thesis: Undervalued. Our ML models identify $105.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -33.9% to -26.5% (+736bps).
| Net Revenue HCRIS | $1.43B |
| Current EBITDA COMPUTED | $-483.1M |
| Operating Margin COMPUTED | -33.9% |
| Occupancy HCRIS | 86.8% |
| Revenue / Bed COMPUTED | $3.1M |
| Net-to-Gross HCRIS | 34.6% |
| Distress Probability ML | 38.1% |
2. Market Context & Competitive Position
NH has 30 Medicare-certified hospitals with a median operating margin of -2.7%. The target's margin of -33.9% places it below the state median. Among 1015 size-comparable peers (228-912 beds), the median margin is -3.8%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (228-912), prioritizing same-state peers. 1015 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| MARY HITCHCOCK MEMORIAL HOSP (Target) | NH | 456 | $1.43B | -33.9% |
| ST. LUKES HOSPITAL | PA | 633 | $8.94B | 87.9% |
| STANFORD HEALTH CARE | CA | 657 | $6.76B | 3.7% |
| UCSF MEDICAL CENTER | CA | 834 | $5.44B | -5.4% |
| UT MD ANDERSON CANCER CENTER | TX | 721 | $4.90B | -0.8% |
| MEMORIAL HOSPITAL FOR CANCER A | NY | 514 | $4.34B | -32.5% |
| CEDARS-SINAI MEDICAL CENTER | CA | 908 | $3.92B | -5.5% |
| STRONG MEMORIAL HOSPITAL | NY | 749 | $3.31B | 5.2% |
| UC DAVIS MEDICAL CENTER | CA | 666 | $3.28B | -11.5% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $105.0M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $30.0M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $28.5M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $28.2M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $17.4M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $913K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-483.1M |
| + RCM Uplift | +$105.0M |
| Pro Forma EBITDA | $-378.1M |
| Current Margin | -33.9% |
| Pro Forma Margin | -26.5% |
| WC Released (1x) | $54.7M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-743.2M | $-2.14B | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-743.2M | $-2.59B | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-668.9M | $-2.49B | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-668.9M | $-2.91B | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-817.5M | $-2.42B | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-817.5M | $-2.93B | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 1015 hospitals with 228-912 beds
- Same-state prioritization (n=2)
- Comp margins: P25=-13.4% / P50=-3.8% / P75=5.2%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.